Test Entry - Detail

BCRABL Kinase Domain Mutation Studies

General

Clinical Use:

Specimens are referred to SA Pathology for testing.
This test detects mutations of the ABL kinase domain that may have occurred in response to therapy with tyrosine kinase inhibitors (TKI) conferring resistance located at amino acids 240-490. Note, that ABL kinase domain mutations are not the only mechanism of TKI resistance. Criteria for testing: Primary resistance - failure to achieve major cytogenetic response (MCR) or BCRABL% <10% by 6 months of imatinib. Secondary resistance - loss of partial or complete haematological response, loss of MCR, clinical progression to accelerated phase or blast crisis or significant increase in BCRABL% (>2-fold increase). The lab may request that small increases in disease level are confirmed in a second sample. Discussion with the clinician must also occur to ensure no compliance issues or dose changes.

Availability:

Samples are tested Monday-Friday.

Aliases/Synonyms:

KDM, t(9:22) Mutations,

Code:

HKDM

Handling Instructions (to laboratory):

Send sample ambient.
Sample must reach laboratory within 48 hours of collection.

Hyperlink:

Reference Interval:

Refer to report or laboratory.

Collection Requirements

Container:

EDTA x 2 (LAV9),

Sample Type:

Blood; Bone Marrow

Minimum Collection Volume:

9mL Blood; 1mL Bone Marrow

Collection Instructions:

Regional Services: Collect sample Monday-Thursday only.
Do not collect prior to public holidays.

Processing Requirements

Alternate Containers:

EDTA x 2 (LAV9)

Processing Instructions:

Store sample at room temperature.
Do not centrifuge sample.

Minimum Assay Volume:

9mL Blood; 1mL Bone Marrow

Stability:

48 hours ambient

Transport Instructions (to testing laboratory):

If sending sample on a Friday afternoon, please contact testing laboratory to inform them of delivery.

Testing Locations

Performed at:

Section	Department	Site	Contact Phone
Molecular	Haematology	Fiona Stanley Hospital	6152 8118

Last Updated : 26-02-2026 11:11